Abstract: The invention relates to novel a high-volume swelling hydrogel which comprises a plurality of pores which are defined by an interpenetrating network, and/or a semi-interpenetrating network and/or simple cross-linked arrangement of a plurality of one or more species of hydrophilic polymers, optionally together with one or more biocompatible polymers and optionally together with one or more plasticising agents, characterised in that at least some of the pores are at least partially collapsed and/or flattened, and further characterised in that the interpenetrating network and/or semi-interpenetrating network and/or cross-linked arrangement which defines the collapsed and/or flattened pores is substantially unbroken. The invention also relates to a process for preparing such hydrogels, and to their use as an appetite suppressant.

Abstract: A nanodelivery system based on globulin-1 S allele, a preparation method therefor and use thereof are provided. The preparation method includes the following steps of: dissolving globulin-1 S allele in a NaCl solution, and performing magnetical stirring until the globulin-1 S allele is completely dissolved to obtain a mixed solution; self-assembly: centrifuging the mixed solution, taking the supernatant to be dispersed into a dispersion solution for self-assembly to obtain a globulin-1 S allele dispersion; and adding hydrophobic plant polyphenol to the globulin-1 S allele dispersion, performing well mixing and centrifuging, and removing the supernatant to obtain the nanodelivery system based on the globulin-1 S allele.

Abstract: A method for evaporatively concentrating a radioactive metal nuclide, including: a first evaporative concentration process in which a radioactive solution formed by dissolving a radioactive metal nuclide in an acidic aqueous solution is heated to evaporate a solvent in the radioactive solution so as to obtain a concentrated liquid containing the radioactive metal nuclide; and a second evaporative concentration process in which a low-boiling organic solvent having a lower boiling point than water is added to the concentrated liquid, and the concentrated liquid is heated to induce azeotropic boiling of the concentrated liquid and the low-boiling organic solvent so as to obtain an evaporative concentrate of the radioactive metal nuclide.

Abstract: This disclosure provides large-scale processes for preparing a modulator of alpha-1 antitrypsin (AAT) activity that may be useful for treating alpha-1 antitrypsin deficiency (AATD), such as 4-(5-(4-fluorophenyl)-6-(tetrahydro-2H-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid (Compound 1), 3-[5-(4-fluorophenyl)-6-isopropyl-1H-pyrrolo[2,3-f]indazol-7-yl]propanoic acid (Compound 2), or a pharmaceutically acceptable salt of any of the foregoing.

Abstract: A substrate (12) for delivering a biologically active substance, the substrate (12) comprising: a cross-linked silicone matrix formed by cross-linking a silicone polymer using at least one crosslinking agent comprising a tetraalkoxysilane, the cross-linked silicone matrix defining a plurality of domains, and a composition contained within the domains of the cross-linked silicone matrix, wherein the composition comprises: at least one monomeric glycol and at least one biologically active substance.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.

Abstract: Formaldehyde is a common component of antimicrobial compositions for preserving animal feeds. However, the use of formaldehyde is coming under pressure and alternative antimicrobial compositions are needed. The present application discloses methods and/or uses of a formaldehyde-free antimicrobial composition comprising formic acid and propionic acid in the making of rendered animal protein compositions or in the inhibiting of the development of Salmonella bacteria in animal by-product compositions (e.g., rendered animal proteins) while maintaining higher protein digestibility comparing with formaldehyde.

Abstract: An object of the present invention is to find a useful means for removing an intraocular membrane. The present invention relates to an agent for use in intraocular membrane peeling surgery, which contains a solution containing a hydrogel-forming material and satisfies the following formula 1 with respect to the dynamic viscoelasticity measured at a temperature of 25 to 40° C. and a frequency of 1 Hz. 0<Vmax?3??(Formula 1) Provided that in the formula 1, Vmax (Pa/sec) is the maximum change rate of the storage elastic modulus after the initiation of gelation.

Abstract: A method for preparing ferrite nanoparticles employing as directing agent an aldehyde or ketone of formula R1—(C?O)R2 is provided. R1 is a linear or branched, saturated or unsaturated carbon chain having a length between 1 and 13 carbon atoms, optionally substituted with an aromatic substituent. R2 is selected from the group consisting of hydrogen, an aromatic ring and a linear or branched, saturated or unsaturated carbon chain having a length between 1 and 10 carbon atoms. When R2 is hydrogen and R1 is an unsaturated carbon chain substituted with an aromatic substituent, the aromatic substituent is located at position 3 or higher with respect to the carbonyl group —(C?O). When R2 is hydrogen and R1 is a saturated carbon chain substituted with an aromatic substituent, the aromatic substituent is located at position 2 or higher with respect to the carbonyl group —(C?O). When the aromatic substituent is located at position 2, the aromatic substituent is the sole substituent at position 2.

Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.

Abstract: Described herein are synthetic cyclic peptide mimetics comprising alternating D-amino acids and L-amino acids and amino acid derivatives, such as aza-amino acids and azasulfuryl-amino acids. Optionally, the cyclic peptide mimetics may be conjugated to another agent via a linker to form cyclic peptide mimetic conjugates. The cyclic peptide mimetics described herein may be used as diagnostic or therapeutic agents for diagnosis or treatment of amyloidogenic diseases.

Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.

Abstract: Provided is a Pt(IV) complex. As a prodrug, the Pt(IV) complex is activated by irradiation to release a Pt(II) complex for the treatment of tumors. Also provided is a pharmaceutical composition including the Pt(IV) complex, and the use of the Pt(IV) complex in the preparation of a drug for treating tumors by means of irradiation activation. Further provided is a kit including the Pt(IV) complex and the description, wherein the description indicates that radiotherapy is performed after administration to treat tumors.

Abstract: An oral care composition comprising high water oral care compositions comprising an orally acceptable carrier, zinc phosphate, a first stannous ion source (i.e., stannous fluoride), and a second stannous ion source (i.e., stannous chloride). Methods and uses for this composition are also described throughout.

Abstract: An adhesive composition for hard tissue repair, comprising a polymerizable monomer (A), a polymer powder (B), and a polymerization initiator (C), wherein the polymerization initiator (C) is represented by the following general formula: [CH3(CH2)m-]2B—O(CH2)nCH3, and in the formula, m and n are each independently an integer from 1 to 4, and the relational expression that 2m+n<=10 is satisfied. The polymerization initiator cannot show coking or ignitability even when in contact with paper, a porous fiber, and the like in air, and is high in fluidity and easy to take a small and correct amount, so as to reduce adverse effects on a human body; and high polymerization activity can be given to a polymerizable composition, so that the polymerizable composition is cured within a short time, and the adhesive composition suitable for hard tissue repair is provided.

Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

Abstract: Disclosed is a composition for treating a joint disease or a connective tissue disease, a composition for cartilage regeneration, or a composition for treating an inflammatory disease, each of the compositions containing dextran, poloxamer or a mixture thereof. The composition stays in the joint or connective tissue for a long time due to the shock-absorbing effect, coating effect or anti-inflammation effect, relieves the shock, covers a damaged portion in a specific manner thereto, or reduces inflammation of an adhered portion. Thus, the composition may be useful for the treatment of the joint disease, the connective tissue disease, or for the cartilage regeneration.

Abstract: The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.

Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

Abstract: The present disclosure relates to liquid dispensing products comprising spray dispensers and methods of using such products.